4//SEC Filing
Ceesay Abraham 4
Accession 0001193125-25-324826
CIK 0002012593other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:11 PM ET
Size
17.1 KB
Accession
0001193125-25-324826
Insider Transaction Report
Form 4
Ceesay Abraham
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-12-17$28.84/sh−2,441$70,393→ 571,305 total - Sale
Common Stock
2025-12-17$30.04/sh−2,792$83,862→ 568,513 total - Sale
Common Stock
2025-12-17$31.04/sh−600$18,622→ 567,913 total - Sale
Common Stock
2025-12-17$28.84/sh−2,147$61,925→ 33,831 total(indirect: By Trust) - Sale
Common Stock
2025-12-17$30.04/sh−2,421$72,722→ 31,410 total(indirect: By Trust) - Sale
Common Stock
2025-12-17$31.04/sh−515$15,985→ 30,895 total(indirect: By Trust)
Holdings
- 81,729(indirect: By Trust)
Common Stock
Footnotes (9)
- [F1]These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F8]Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F9]Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Rapport Therapeutics, Inc.
CIK 0002012593
Entity typeother
Related Parties
1- filerCIK 0001722140
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:11 PM ET
- Size
- 17.1 KB